stephen ghiglieri  meddata inc  zoominfocom stephen f ghiglieri  oakland ca  intelius sign in we found stephen f ghiglieri in oakland ca stephen f ghiglieri intelius found that stephen f ghiglieri is a male between  and  years old from oakland ca we have connected them to  addresses  phones and  relatives or associates also known as stephen p ghiglieri get report now age stephen f ghiglieri is in his s stephen has lived in oakland ca san leandro ca brecksville oh stephens relatives carol ghiglieri andrew ghiglieri arthur ghiglieri mary ghiglieri stephen f ghiglieri zodiac signaries gendermale professional status chief financial officer at meddata inc get report now want to know more about stephen get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about stephen or use our people search engine to find others get background check on stephen f ghiglieri get a criminal check on stephen f ghiglieri get a public record report on stephen f ghiglieri get a people search report on stephen f ghiglieri stephen f ghiglieris contact information known cities lived in find out where stephen f ghiglieri has lived as well as stephen f ghiglieris phone numbers and email addresses stephen f ghiglieri has lived in  states california address for stephen f ghiglieri  w a oakland ca has lived in oakland ca san leandro ca get full address report phone numbers associated with stephen f ghiglieri    oakland ca    oakland ca    san francisco ca get full phone report email addresses associated with stephen f ghiglieri srcom srcom sncom get email report stephen f ghiglieris education information known schools attended learn about stephen f ghiglieris academic history find out which schools stephen f ghiglieri attended the dates attended as well as the degrees stephen f ghiglieri received the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act stephen f ghiglieri has attended  schools california state universityeast bay  –  stephen f ghiglieri has a ba in business administration california state universityeast bay  –  stephen f ghiglieri has a ba business administration in business administration stephen f ghiglieris professional information information regarding stephen f ghiglieris professional history find out previous places stephen f ghiglieri has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act stephen f ghiglieri has worked at  places company meddata inc title chief financial officer company neurogesx  inc title executive vice president stephen f ghiglieris experience title chief financial officer company meddata inc job details company size  mil to less than  mil  employee range  to less than  meddata a mednax nyse md company is a technologyenabled services organization that improves financial outcomes for hospitals by enhancing the patient experience and expanding their access to healthcare the meddata managed services platform includes a range of patient access and communications revenue cycle management and consulting and analytics solutions for more than  years the company has been providing innovative services and technologies to the medical community and serving millions of patients across numerous medical specialties meddata currently serves more than  physicians at a growing network of  facilities nationwide from its headquarters in brecksville ohio and  regional offices across the us title executive vice president company neurogesx  inc job details company size  mil to less than  mil  employee range  to less than  additional professional information on stephen f ghiglieri see stephen f ghiglieris linkedin profile stephen f ghiglieris social network and potential email matches find out potential social network profiles and potential email usernamed for stephen f ghiglieri stephen f ghiglieris known social networks and potential email matches find all of stephen f ghiglieris social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches stephen ghiglieri username matches stephenghiglieri ghiglieristephen stephenghiglieri ghiglieristephen stephenghiglieri ghiglieristephen stephenghiglieri ghiglieristephen sghiglieri popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches s ghiglieri intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here neurogesx appoints stephen ghiglieri as chief financial officer new cfo brings experience in ipos acquisitions and licensing  business wire neurogesx appoints stephen ghiglieri as chief financial officer new cfo brings experience in ipos acquisitions and licensing biowirek october    am eastern daylight time san carlos califbusiness wireoct  neurogesx today announced it has appointed stephen f ghiglieri as chief financial officer mr ghiglieri who has experience in public offerings acquisitions and licensing for life sciences and software companies will assume responsibility for all financial aspects of neurogesxs business activities stephens track record in helping emerging growth companies from the rd phase through product introductions makes him an excellent match for neurogesx said anthony a ditonno ceo and president of neurogesx as we continue making progress in our clinical trials and as we continue to look at opportunities to expand our product portfolio stephens effective management of our financial resources will play an important role in our success neurogesx is conducting two sets of pivotal trials including the treatment of postherpetic neuralgia associated with shingles and the treatment of painful hivassociated neuropathy mr ghiglieri was most recently chief financial officer of hansen medical inc palo alto ca an early state medical device company earlier he was cfo of oacis healthcare systems inc san rafael ca where he managed the companys initial public offering and subsequent acquisition by saic mr ghiglieri has also served as cfo of andromedia inc and avolent inc both san francisco software companies where he managed ipo ma and venture financing transactions including the sale of andromedia to macromedia inc he also held financial management positions with oclassen pharmaceuticals inc and pricewaterhousecoopers mr ghiglieri received his ba in business administration from california state university at hayward he is a member of the american institute of certified public accountants the california society of certified public accountants and the financial executive institute about neurogesx neurogesx neurogeesix is a privately held specialty pharmaceutical company focusing on the development of products for the treatment of nerve signaling disorders the companys initial products are focused on the treatment of chronic and acute pain the companys first product a topical treatment for neuropathic pain has been evaluated in a phase ii randomized double blind trial for the treatment of pains associated with shingles two phase ii iii multicenter pivotal clinical trials focused on this indication are currently enrolling patients the company is also conducting phase iiiii pivotal trials for the treatment of painful hivassociated neuropathy neurogesx has raised  million in total equity investments since its first funding round in june  investors include alta partners arch venture partners montreux equity partners grove street advisors affiliated fund tiaa teachers insurance and annuity association duke university university of north carolina and walden international for more information about neurogesx go to wwwneurogesxcom note to editors neurogesx is a trademark of neurogesx inc all other trademarks and registered trademarks are those of their respective companies contacts neurogesx incanthony a ditonno aditonnoneurogesxcom orjackman communicationsmike jackman mikejackmancom contacts neurogesx incanthony a ditonno aditonnoneurogesxcom orjackman communicationsmike jackman mikejackmancom search advanced news search advanced news search log in sign up galena biopharma appoints stephen f ghiglieri as executive vice president and chief financial officer  marketwatch bulletin investor alert press release nov    am edt galena biopharma appoints stephen f ghiglieri as executive vice president and chief financial officer san ramon calif nov   globe newswire via comtex  galena biopharma inc quoteszigmancomposite gale   a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs today announced that stephen f ghiglieri has been appointed as the companys executive vice president and chief financial officer effective immediately stephen has  years of senior level finance and operating experience primarily in the life sciences industry and has been integral to the growth of numerous companies from emerging stage through commercial approval and market launch said mark w schwartz phd president and chief executive officer  stephen is a welcome addition to our management team as we restructure our organization and position ourselves to progress our rich clinical pipeline  we are preparing to initiate a pivotal trial next year and we look forward to providing a corporate update on the progress of all of our programs on our quarterly call next week i am excited to be joining galena at this important time in the companys history  galena is currently refocusing its efforts with a backbone of valuable hematology and immunotherapy assets i welcome the opportunity to join the team and provide guidance and leadership to help advance the company through its next stages of development i believe we have the opportunity to build significant shareholder value by executing on a relatively lower risk clinical and regulatory development program with gale and supporting ongoing investigator and partner sponsored studies with our immunotherapy assets commented mr ghiglieri stephen f ghiglieri joins galena biopharma with more than  years in senior level finance and operations roles at both biotechnology and technology companies  prior to galena biopharma mr ghiglieri served as cfo of meddata inc a private equity backed healthcare services company that was sold to mednax a publicly traded national medical group  previously he spent nearly  years at neurogesx ending his tenure as the companys executive vice president chief operating officer and cfo  prior to that he served as the cfo of hansen medical inc a medical device company  he also held senior level finance positions at two other healthcare companies oacis healthcare systems inc and oclassen pharmaceuticals inc  additionally he was also the cfo and corporate secretary for two technology software companies avolent inc and andromedia inc mr ghiglieri began his career as an audit manager of pricewaterhousecoopers llp he received a bachelor of science in business administration from california state university hayward where he graduated magna cum laude mr ghiglieri is also a certified public accountant inactive about galena biopharma galena biopharma inc is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs galenas pipeline consists of multiple midtolatestage clinical assets led by its hematology asset gale and novel cancer immunotherapy programs including neuvaxtm nelipepimuts and galegale for more information visit wwwgalenabiopharmacom  forwardlooking statements this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of   such statements include but are not limited to statements about the progress of the development of galenas product candidates patient enrollment in our clinical trials as well as other statements related to the progress and timing of our development activities present or future licensing collaborative or financing arrangements expected outcomes with regulatory agencies and projected market opportunities for product candidates or that otherwise relate to future periods these forwardlooking statements are subject to a number of risks uncertainties and assumptions including those identified under risk factors in galenas annual report on form k for the year ended december   and most recent quarterly reports on form q filed with the sec actual results may differ materially from those contemplated by these forwardlooking statements galena does not undertake to update any of these forwardlooking statements to reflect a change in its views or events or circumstances that occur after the date of this press release neuvax is a trademark of galena biopharma inc contact remy bernarda svp investor relations  corporate communications   irgalenabiopharmacom copyright c  globenewswire inc all rights reserved quoteszigmancomposite add to watchlist gale galena biopharma inc us  us nasdaq     volume  july   p pe rationa dividend yieldna market cap million rev per employeena most popular  market extra wall street isn’t ready for a point tumble in the dow industrials  all the companies in jeff bezos’s empire in one large chart  market snapshot sp  nasdaq finish lower after amazon disappointment dow closes at record  marketwatch first take intel earnings have message for amd and nvidia ‘bring it on’  sectorwatch silicon valleys corporatecampus building boom is a cautionary tale find a broker partner center » featured stories seeing america again through new eyes how to dig yourself out of debt move over tesla karma unveils its hybrid sports car the salary you need to afford a home in these  cities why opec will never cut production again log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pwall street isn’t ready for a point tumble in the dow industrials pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stephen ghiglieri galena biopharma inc profile  biography  bloomberg feedback stephen ghiglieri interim ceocfocao galena biopharma inc career history interim ceocfocao galena biopharma inc present interim ceocfo galena biopharma inc  exec vpcfo galena biopharma inc  chief financial officer meddata inc unknown cfosecretary neurogesx inc  chief financial officer hansen medical inc  exec vpcfosecretary avolent inc  vpfinancecfosecretary andromedia inc  vpfin  admincfosecretary oacis healthcare systems inc  controller oclassen pharmaceuticals inc  audit manager pricewaterhousecoopers llp  exec vpcfocoosecretary neurogesx inc unknown show more website wwwgalenabiopharmacom corporate information address  crow canyon place suite  san ramon ca united states phone  fax  web url wwwgalenabiopharmacom from the web personal information education california state university bachelors degree business administration awards  publications certificates certified public accountant cpa memberships other memberships american inst of certified public accountants member california society of certified public accountants member financial executive inst member show more sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data galena biopharma appoints stephen f ghiglieri as executive vice president and chief financial officer  pt community skip to main content pt community registersign in search form search home news ptcurrent issue past issues masthead digital edition subscribe pt tv authors about contact us   ingrezza® valbenazine tablets‎ zurampic® lesinurad tabletsplease click for full prescribing information including boxed warning you are herehome galena biopharma appoints stephen f ghiglieri as executive vice president and chief financial officer san ramon calif nov   globe newswire  galena biopharma inc nasdaqgale a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs today announced that stephen f ghiglieri has been appointed as the company’s executive vice president and chief financial officer effective immediately “stephen has  years of senior level finance and operating experience primarily in the life sciences industry and has been integral to the growth of numerous companies from emerging stage through commercial approval and market launch” said mark w schwartz phd president and chief executive officer  “stephen is a welcome addition to our management team as we restructure our organization and position ourselves to progress our rich clinical pipeline  we are preparing to initiate a pivotal trial next year and we look forward to providing a corporate update on the progress of all of our programs on our quarterly call next week” “i am excited to be joining galena at this important time in the company’s history  galena is currently refocusing its efforts with a backbone of valuable hematology and immunotherapy assets i welcome the opportunity to join the team and provide guidance and leadership to help advance the company through its next stages of development i believe we have the opportunity to build significant shareholder value by executing on a relatively lower risk clinical and regulatory development program with gale and supporting ongoing investigator and partner sponsored studies with our immunotherapy assets” commented mr ghiglieri stephen f ghiglieri joins galena biopharma with more than  years in senior level finance and operations roles at both biotechnology and technology companies  prior to galena biopharma mr ghiglieri served as cfo of meddata inc a private equity backed healthcare services company that was sold to mednax a publicly traded national medical group  previously he spent nearly  years at neurogesx ending his tenure as the company’s executive vice president chief operating officer and cfo  prior to that he served as the cfo of hansen medical inc a medical device company  he also held senior level finance positions at two other healthcare companies oacis healthcare systems inc and oclassen pharmaceuticals inc  additionally he was also the cfo and corporate secretary for two technology software companies avolent inc and andromedia inc mr ghiglieri began his career as an audit manager of pricewaterhousecoopers llp he received a bachelor of science in business administration from california state university hayward where he graduated magna cum laude mr ghiglieri is also a certified public accountant inactive about galena biopharma galena biopharma inc is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs galena’s pipeline consists of multiple midtolatestage clinical assets led by its hematology asset gale and novel cancer immunotherapy programs including neuvax™ nelipepimuts and galegale for more information visit wwwgalenabiopharmacom forwardlooking statements this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of   such statements include but are not limited to statements about the progress of the development of galena’s product candidates patient enrollment in our clinical trials as well as other statements related to the progress and timing of our development activities present or future licensing collaborative or financing arrangements expected outcomes with regulatory agencies and projected market opportunities for product candidates or that otherwise relate to future periods these forwardlooking statements are subject to a number of risks uncertainties and assumptions including those identified under “risk factors” in galena’s annual report on form k for the year ended december   and most recent quarterly reports on form q filed with the sec actual results may differ materially from those contemplated by these forwardlooking statements galena does not undertake to update any of these forwardlooking statements to reflect a change in its views or events or circumstances that occur after the date of this press release neuvax is a trademark of galena biopharma inc contact contact remy bernarda svp investor relations  corporate communications   irgalenabiopharmacomthursday november     stay in touch newsletters available pt and drug management daily news pt table of contents monthly contact us editorial j stephen mciver editoradvertising maureen dwyer liberti vice president group publisherproduction dawn flook director of production servicescirculation jackie ott circulation managerwebmaster webmaster industry announcements affimed presents data on firstinclass bcmatargeting immune cell engager afm at asco annual meeting  share buyback week  novartis drug tasigna receives eu approval for inclusion of treatmentfree remission tfr data in product label basilea announces presentation of interim phase a clinical data with anticancer drug candidate bal at asco meeting targovax presents further positive clinical data from tg phase iii trial at  asco annual meeting addex annual general meeting scheduled for  june  valneva to present at jefferies  global healthcare conference in new york targovax announces formal agenda for  capital markets updates in oslo and london lundbeck obtains rights to breakthrough research in alzheimer’s disease veloxis pharmaceuticals as announces agreement with chiesi farmaceutici spa to commercialize envarsus xr in china more from globe newswire current issue of pt july  user login username  password  create new account request new password microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft galena biopharma board of directors appoints stephen f ghiglieri as interim chief executive officer nasdaqgale english français register sign in galena biopharma board of directors appoints stephen f ghiglieri as interim chief executive officer february    et  source galena biopharma inc san ramon calif feb   globe newswire  galena biopharma inc nasdaqgale a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs today announced that the company’s board of directors appointed stephen f ghiglieri as interim chief executive officer effective today  mr ghiglieri will also continue to serve as the company’s chief financial officer “on behalf of the entire board of directors we are pleased to appoint stephen as our interim ceo” said sanford j hillsberg galena’s chairman of the board of directors “we believe his prior public company experience and oversight will prove valuable to galena as we evaluate strategic alternatives for the company focused on maximizing stockholder value” “over the course of my career i have been involved with various companies that have gone through transitions and believe that my experience will be beneficial to all of our stakeholders as we seek an optimal outcome for galena i look forward to working with our board of directors and management team to ensure the company continues to execute as we identify opportunities to enhance our value” added mr ghiglieri mr ghiglieri joined galena biopharma in november  after previously consulting for the company  he has more than  years in senior level finance and operational roles at both biotechnology and technology companies prior to galena mr ghiglieri served as cfo of meddata inc a private equity backed healthcare services company that was sold to mednax a publicly traded national medical group previously he spent nearly  years at neurogesx ending his tenure as the company’s executive vice president chief operating officer and cfo prior to that he served as the cfo of hansen medical inc a medical device company he also held senior level finance positions at two other healthcare companies oacis healthcare systems inc and oclassen pharmaceuticals inc  additionally he was the cfo and corporate secretary for two technology software companies avolent inc and andromedia inc mr ghiglieri began his career as an audit manager of pricewaterhousecoopers llp he received a bachelor of science in business administration from california state university hayward where he graduated magna cum laude mr ghiglieri is also a certified public accountant inactive about galena biopharma galena biopharma inc is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs galena’s pipeline consists of multiple midtolatestage clinical assets led by its hematology asset gale and its novel cancer immunotherapy programs including neuvax™ nelipepimuts and galegale for more information visit wwwgalenabiopharmacom forwardlooking statements this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of   such statements include but are not limited to statements about the progress of the strategic alternatives evaluation  development of galena’s product candidates patient enrollment in our clinical trials as well as other statements related to the progress and timing of our development activities galena’s current and prospective financial condition liquidity and access to capital present or future licensing collaborative or financing arrangements expected outcomes with regulatory agencies and projected market opportunities for product candidates or that otherwise relate to future periods these forwardlooking statements are subject to a number of risks uncertainties and assumptions including those identified under “risk factors” in galena’s annual report on form k for the year ended december   most recent quarterly reports on form q current reports on form k and and on the prospectus supplement to the registration statement related to the public offering filed with the sec actual results may differ materially from those contemplated by these forwardlooking statements galena does not undertake to update any of these forwardlooking statements to reflect a change in its views or events or circumstances that occur after the date of this press release neuvax is a trademark of galena biopharma inc source galena biopharma inccontact remy bernarda svp investor relations  corporate communications   irgalenabiopharmacom related articles other press releases by galena biopharma inc galena biopharma provides corporate update july    galena biopharma reports first quarter  financial results may    galena biopharma presents positive interim safety data on the neuvax™ nelipepimuts clinical trial in combination with trastuzumab in highrisk her  patients at the aacr annual meeting  april    galena biopharma presents positive final gale e phase a clinical trial data march    galena biopharma reports fourth quarter and year end  financial results and provides a corporate update march    profile galena biopharma inc   subscribe via rss  subscribe via atom  javascript san ramon california united states contact data contact remy bernarda svp investor relations  corporate communications   irgalenabiopharmacom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files galena biopharma inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved galena biopharma inc gale stephen f ghiglieri has been appointed interim ceo  smarter analyst  login  connect premium services galena biopharma inc gale stephen f ghiglieri has been appointed interim ceo corey williamsfebruary    pm edt share on galena biopharma inc nasdaqgale announced that the company’s board of directors appointed stephen f ghiglieri as interim chief executive officer effective today  mr ghiglieri will also continue to serve as the company’s chief financial officer “on behalf of the entire board of directors we are pleased to appoint stephen as our interim ceo” said sanford j hillsberg galena’s chairman of the board of directors “we believe his prior public company experience and oversight will prove valuable to galena as we evaluate strategic alternatives for the company focused on maximizing stockholder value” “over the course of my career i have been involved with various companies that have gone through transitions and believe that my experience will be beneficial to all of our stakeholders as we seek an optimal outcome for galena i look forward to working with our board of directors and management team to ensure the company continues to execute as we identify opportunities to enhance our value” added mr ghiglieri mr ghiglieri joined galena biopharma in november  after previously consulting for the company  he has more than  years in senior level finance and operational roles at both biotechnology and technology companies prior to galena mr ghiglieri served as cfo of meddata inc a private equity backed healthcare services company that was sold to mednax a publicly traded national medical group previously he spent nearly  years at neurogesx ending his tenure as the company’s executive vice president chief operating officer and cfo prior to that he served as the cfo of hansen medical inc a medical device company he also held senior level finance positions at two other healthcare companies oacis healthcare systems inc and oclassen pharmaceuticals inc  additionally he was the cfo and corporate secretary for two technology software companies avolent inc and andromedia inc mr ghiglieri began his career as an audit manager of pricewaterhousecoopers llp he received a bachelor of science in business administration from california state university hayward where he graduated magna cum laude mr ghiglieri is also a certified public accountant inactive shares of galena biopharma are down nearly  to  in afterhours trading gale has a year high of  and a year low of  the stock’s day moving average is  and its day moving average is  on the ratings front gale has been the subject of a number of recent research reports in a report issued on february  fbr analyst vernon bernardino downgraded gale to hold with a price target of  which represents a potential upside of  from where the stock is currently trading on february  maxim’s jason mccarthy downgraded the stock to hold according to tiprankscom which ranks over  financial analysts and bloggers to gauge the performance of their past recommendations vernon bernardino and jason mccarthy have a yearly average loss of  and  respectively bernardino has a success rate of  and is ranked  out of  analysts while mccarthy has a success rate of  and is ranked  galena biopharma inc is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs the company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects its products include abstral sublingual tablets and zuplenz oral soluble film  galegalena biopharma inc you may also like see what other wall street analystsfinancial bloggers say about gale which stocks are top  analysts buying find out here see what corporate insiders are buying find morerelated articles wednesday’s market insights dryships inc drys gilead sciences inc gild and galena biopharma gale harriet lefton february   contributor opinionsmost popular fbr downgrades galena biopharma inc gale right as stock skyrockets  julie lamb editor february   healthcaremost popular this analyst has had enough with galena biopharma inc gale jason cohen editor february   healthcareinsights stay ahead of everyone else get the latest stock news alerts thank you for signing up error signing up please try again sign me up galena biopharma inc gale stephen f ghiglieri has been appointed interim ceo  smarter analyst  login  connect premium services galena biopharma inc gale stephen f ghiglieri has been appointed interim ceo corey williamsfebruary    pm edt share on galena biopharma inc nasdaqgale announced that the company’s board of directors appointed stephen f ghiglieri as interim chief executive officer effective today  mr ghiglieri will also continue to serve as the company’s chief financial officer “on behalf of the entire board of directors we are pleased to appoint stephen as our interim ceo” said sanford j hillsberg galena’s chairman of the board of directors “we believe his prior public company experience and oversight will prove valuable to galena as we evaluate strategic alternatives for the company focused on maximizing stockholder value” “over the course of my career i have been involved with various companies that have gone through transitions and believe that my experience will be beneficial to all of our stakeholders as we seek an optimal outcome for galena i look forward to working with our board of directors and management team to ensure the company continues to execute as we identify opportunities to enhance our value” added mr ghiglieri mr ghiglieri joined galena biopharma in november  after previously consulting for the company  he has more than  years in senior level finance and operational roles at both biotechnology and technology companies prior to galena mr ghiglieri served as cfo of meddata inc a private equity backed healthcare services company that was sold to mednax a publicly traded national medical group previously he spent nearly  years at neurogesx ending his tenure as the company’s executive vice president chief operating officer and cfo prior to that he served as the cfo of hansen medical inc a medical device company he also held senior level finance positions at two other healthcare companies oacis healthcare systems inc and oclassen pharmaceuticals inc  additionally he was the cfo and corporate secretary for two technology software companies avolent inc and andromedia inc mr ghiglieri began his career as an audit manager of pricewaterhousecoopers llp he received a bachelor of science in business administration from california state university hayward where he graduated magna cum laude mr ghiglieri is also a certified public accountant inactive shares of galena biopharma are down nearly  to  in afterhours trading gale has a year high of  and a year low of  the stock’s day moving average is  and its day moving average is  on the ratings front gale has been the subject of a number of recent research reports in a report issued on february  fbr analyst vernon bernardino downgraded gale to hold with a price target of  which represents a potential upside of  from where the stock is currently trading on february  maxim’s jason mccarthy downgraded the stock to hold according to tiprankscom which ranks over  financial analysts and bloggers to gauge the performance of their past recommendations vernon bernardino and jason mccarthy have a yearly average loss of  and  respectively bernardino has a success rate of  and is ranked  out of  analysts while mccarthy has a success rate of  and is ranked  galena biopharma inc is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs the company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects its products include abstral sublingual tablets and zuplenz oral soluble film  galegalena biopharma inc you may also like see what other wall street analystsfinancial bloggers say about gale which stocks are top  analysts buying find out here see what corporate insiders are buying find morerelated articles wednesday’s market insights dryships inc drys gilead sciences inc gild and galena biopharma gale harriet lefton february   contributor opinionsmost popular fbr downgrades galena biopharma inc gale right as stock skyrockets  julie lamb editor february   healthcaremost popular this analyst has had enough with galena biopharma inc gale jason cohen editor february   healthcareinsights stay ahead of everyone else get the latest stock news alerts thank you for signing up error signing up please try again sign me up galena biopharma inc  galena biopharma board of directors appoints stephen f ghiglieri as interim chief executive officer skip to main content contact us home»investors»press releases»press release details press release details all news galena biopharma board of directors appoints stephen f ghiglieri as interim chief executive officer feb   download this press release pdf format opens in new window  san ramon calif feb   globe newswire  galena biopharma inc nasdaqgale a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs today announced that the company’s board of directors appointed stephen f ghiglieri as interim chief executive officer effective today  mr ghiglieri will also continue to serve as the company’s chief financial officer “on behalf of the entire board of directors we are pleased to appoint stephen as our interim ceo” said sanford j hillsberg galena’s chairman of the board of directors “we believe his prior public company experience and oversight will prove valuable to galena as we evaluate strategic alternatives for the company focused on maximizing stockholder value” “over the course of my career i have been involved with various companies that have gone through transitions and believe that my experience will be beneficial to all of our stakeholders as we seek an optimal outcome for galena i look forward to working with our board of directors and management team to ensure the company continues to execute as we identify opportunities to enhance our value” added mr ghiglieri mr ghiglieri joined galena biopharma in november  after previously consulting for the company  he has more than  years in senior level finance and operational roles at both biotechnology and technology companies prior to galena mr ghiglieri served as cfo of meddata inc a private equity backed healthcare services company that was sold to mednax a publicly traded national medical group previously he spent nearly  years at neurogesx ending his tenure as the company’s executive vice president chief operating officer and cfo prior to that he served as the cfo of hansen medical inc a medical device company he also held senior level finance positions at two other healthcare companies oacis healthcare systems inc and oclassen pharmaceuticals inc  additionally he was the cfo and corporate secretary for two technology software companies avolent inc and andromedia inc mr ghiglieri began his career as an audit manager of pricewaterhousecoopers llp he received a bachelor of science in business administration from california state university hayward where he graduated magna cum laude mr ghiglieri is also a certified public accountant inactive about galena biopharma galena biopharma inc is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs galena’s pipeline consists of multiple midtolatestage clinical assets led by its hematology asset gale and its novel cancer immunotherapy programs including neuvax™ nelipepimuts and galegale for more information visit wwwgalenabiopharmacom forwardlooking statements this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of   such statements include but are not limited to statements about the progress of the strategic alternatives evaluation  development of galena’s product candidates patient enrollment in our clinical trials as well as other statements related to the progress and timing of our development activities galena’s current and prospective financial condition liquidity and access to capital present or future licensing collaborative or financing arrangements expected outcomes with regulatory agencies and projected market opportunities for product candidates or that otherwise relate to future periods these forwardlooking statements are subject to a number of risks uncertainties and assumptions including those identified under “risk factors” in galena’s annual report on form k for the year ended december   most recent quarterly reports on form q current reports on form k and and on the prospectus supplement to the registration statement related to the public offering filed with the sec actual results may differ materially from those contemplated by these forwardlooking statements galena does not undertake to update any of these forwardlooking statements to reflect a change in its views or events or circumstances that occur after the date of this press release neuvax is a trademark of galena biopharma inc source galena biopharma inc contact remy bernarda svp investor relations  corporate communications   irgalenabiopharmacom source galena biopharma inc all news quick links events  presentation  sec filings  financials email alerts email address   mailing lists  press releases sec filings events  presentations eod stock quote   enter the code shown above   copyright  galena biopharma galena biopharma inc   crow canyon place suite   san ramon ca   gale  legal powered by q inc  opens in new window